Skip to content

Bioventus BVS Weighted-Average Discount Rate - Finance Leases

Weighted-Average Discount Rate - Finance Leases at other companies

Globus Medical logo
Globus MedicalGMED
Axogen logo
AxogenAXGN

Other financials

Income statement

See full
Revenue$132.1M+6.6%
Gross profit$90.8M+9.3%
Operating income$8.4M+72.8%
Net income$3.1M+218%
EPS (diluted)$0.04+200%

Balance sheet

See full
Cash & equivalents$35.8M+57.2%
Total debt$288.4M-21.2%
Total equity$188.9M+27.5%
Total assets$650.5M-5.9%

Cash flow

See full
Operating cash flow$8.9M+146%
CapEx$574.0K-30.5%
Free cash flow$8.4M+141%

Valuation

See full
Market cap$659.19M+51.7%
Enterprise value$911.76M+17.2%
P/E23.1×
P/S1.1×+0.4×

Profitability

See full
Gross margin68.7%+1.2pp
Operating margin10%
Net margin4.9%+3.2pp
FCF margin17.5%+13.2pp

Returns & leverage

See full
Return on equity16.9%+10.9pp
Debt / equity1.5×-0.9×
Current ratio1.7×+0.3×

Where this comes from

Reported directly by Bioventus in its filing.

Tagged under the XBRL concept us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent.

The official record: Bioventus’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bioventus's weighted-average discount rate - finance leases.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bioventus's weighted-average discount rate - finance leases?
Bioventus (BVS) reported weighted-average discount rate - finance leases of $0.08 in Q1 2026.
How has Bioventus's weighted-average discount rate - finance leases changed year-over-year?
Bioventus's weighted-average discount rate - finance leases decreased by 0.0% year-over-year, from $0.08 to $0.08.
What is the long-term trend for Bioventus's weighted-average discount rate - finance leases?
Over 3 years (2022 to 2025), Bioventus's weighted-average discount rate - finance leases has grown at a 34.9% compound annual growth rate (CAGR), from $0.03 to $0.08.